Radium-223 (Xofigo)
Castration-resistant prostate cancer that has spread to the bone can be treated with this radioactive substance. Alpha-emitting radionuclide radium-223 targets the areas of the bone where cancer is causing changes and mimics calcium. This therapy conveys radiation particles straightforwardly to growths tracked down in the bone, restricting harm to solid tissue, including the bone marrow, where ordinary platelets are made. For six months, radium-223 is administered intravenously (IV) once per month. A radiation oncologist or a nuclear medicine physician will administer this treatment. Throughout this treatment, your medical oncologist should continue to monitor your progress to ensure that the treatment is effective and that any potential side effects are managed. Radium-233 treatment does not always lower PSA, so patients should not anticipate significant PSA levels dropping during treatment; in fact, PSA levels may frequently rise.
This treatment should not be given to some people, especially those with prostate cancer that has spread to the liver, lungs, or both, or with lymph nodes that are three centimeters or larger in diameter. Radium-223 ought not be utilized in mix with abiraterone and prednisone since that blend builds the gamble of bone cracks. Check with your doctor to see if you might benefit from taking this medication.

Comments
Post a Comment